XASXAGN
Market cap50mUSD
Jan 08, Last price
0.64AUD
1D
0.79%
1Q
-11.81%
IPO
47.67%
Name
Argenica Therapeutics Ltd
Chart & Performance
P/E
—
P/S
31.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
+48.46%
Net income
-5m
L+13.80%
CFO
-5m
L+53.34%
Profile
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | 2,598 48.46% | 1,750 575.38% | 259 -12.49% | ||
Cost of revenue | 8,269 | 6,625 | 4,244 | ||
Unusual Expense (Income) | |||||
NOPBT | (5,671) | (4,875) | (3,985) | ||
NOPBT Margin | |||||
Operating Taxes | (2,089) | (1,378) | (259) | ||
Tax Rate | |||||
NOPAT | (3,582) | (3,497) | (3,726) | ||
Net income | (5,479) 13.80% | (4,815) 17.71% | (4,091) 297.35% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 11,634 | 3,725 | 5,132 | ||
BB yield | -14.35% | -11.34% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (15,913) | (9,339) | (8,914) | ||
| Cash flow | |||||
Cash from operating activities | (5,061) | (3,300) | (3,362) | ||
CAPEX | |||||
Cash from investing activities | 50 | (50) | |||
Cash from financing activities | 11,634 | 3,725 | 5,132 | ||
FCF | (3,582) | (3,497) | (3,726) | ||
| Balance | |||||
Cash | 15,913 | 9,339 | 8,914 | ||
Long term investments | |||||
Excess cash | 15,783 | 9,252 | 8,902 | ||
Stockholders' equity | 13,951 | 7,666 | 8,307 | ||
Invested Capital | (659) | ||||
ROIC | 530.61% | ||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 103,707 | 87,578 | 73,926 | ||
Price | 0.78 108.53% | 0.38 | |||
Market cap | 81,099 146.94% | 32,842 | |||
EV | 65,186 | 23,503 | |||
EBITDA | (5,671) | (4,875) | (3,985) | ||
EV/EBITDA | |||||
Interest | 1 | 822 | |||
Interest/NOPBT | |||||